Fig. 3.

CML and AML tumour foci in ovarian cortex are sensitive to GSK1070916. HE staining showing that CML tumour foci (JURL-MK, K562 and MEG-01) and AML tumour foci (KG-1a, NB4 and NOMO-1) were abundantly present in control human ovarian cortex treated with solvent-only (panel a–f, white arrowheads indicate tumour foci, the white arrow points at a primordial follicle). After treatment for 24 h with 1 μM GSK1070916 followed by an additional culture for 6 days, tumour foci of JURL-MK1, K562, KG-1a, NB4 and NOMO-1 cells could no longer be detected in ovarian cortex tissue. Large syncytia with sometimes large vacuoles (panel g–r, black arrowheads indicate syncytia) were present in cortex tissue harbouring JURL-MK1, K562 and KG1-a cells after treatment with 1 μm GSK1070916. Apoptotic bodies (grey arrow heads) were present in all cell lines in ovarian cortex tissue after purging except for MEG-01, whereas NB4 and NOMO-1 showed almost exclusively apoptotic bodies with few small syncytia (panel q–r). In contrast to the other five cell lines, MEG-01 showed mostly tumour foci harbouring morphologically normal tumour cells (white arrowheads in panel i and o) next to few small syncytia with up to four nuclei after treatment (black arrowhead in panel o). Scale bars represent 20 μm in panel a–l and 10 μm in panel m-r